The data shown below were collected from the profiles of 7 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
| Title |
Mifepristone for uterine fibroids
|
|---|---|
| Published in |
Cochrane database of systematic reviews, August 2012
|
| DOI | 10.1002/14651858.cd007687.pub2 |
| Pubmed ID | |
| Authors |
Mario Tristan, Leonardo J Orozco, Antonia Steed, Anggie Ramirez-Morera, Peter Stone |
| Abstract |
Uterine fibroids are the most common benign uterine tumours present in women of reproductive age. Mifepristone (RU-486) competitively binds and inhibits progesterone receptors. Studies have suggested that fibroid growth depends on the sexual steroids. Mifepristone has been shown to decrease fibroid size. This review summarises the effects of mifepristone treatment on fibroids and the associated adverse effects as described in randomised controlled trials. |
X Demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 29% |
| Chile | 1 | 14% |
| United Kingdom | 1 | 14% |
| Unknown | 3 | 43% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 7 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 254 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | <1% |
| United States | 1 | <1% |
| Unknown | 252 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 43 | 17% |
| Student > Bachelor | 29 | 11% |
| Researcher | 24 | 9% |
| Student > Ph. D. Student | 20 | 8% |
| Student > Postgraduate | 17 | 7% |
| Other | 46 | 18% |
| Unknown | 75 | 30% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 98 | 39% |
| Nursing and Health Professions | 18 | 7% |
| Psychology | 11 | 4% |
| Biochemistry, Genetics and Molecular Biology | 8 | 3% |
| Pharmacology, Toxicology and Pharmaceutical Science | 8 | 3% |
| Other | 28 | 11% |
| Unknown | 83 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 17. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 April 2023.
All research outputs
#2,213,705
of 25,939,391 outputs
Outputs from Cochrane database of systematic reviews
#4,489
of 13,166 outputs
Outputs of similar age
#13,880
of 187,062 outputs
Outputs of similar age from Cochrane database of systematic reviews
#67
of 212 outputs
Altmetric has tracked 25,939,391 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 91st percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 13,166 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 35.2. This one has gotten more attention than average, scoring higher than 65% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 187,062 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 92% of its contemporaries.
We're also able to compare this research output to 212 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 67% of its contemporaries.